

Remarks

The above new claims 30-41 are directed to polypeptides comprising an amino acid sequence from the PDGF A chain and compositions comprising these polypeptides. Claims 30-40 have been copied from U.S. Patent No. 4,889,919 ("the '919 patent") for purposes of preserving applicants' right to provoke an interference at a later date. Applicants, in copying these claims, have corrected what appear to be typographical errors in the issued '919 claims. Specifically, claim 1 of the issued patent (corresponding to claim 30 herein) specifies a Phe at position 27 (this corresponds to position 121 of Figure 1 of the instant application). However, it appears that Pro was intended since the remaining claims of the issued patent all recite Pro at this position. Furthermore, no mention is made in the specification of an amino acid substitution at this position.

An additional error appears in claim 2 of the '919 patent (claim 31 herein). This claim appears to be missing an Arg at position 81 (corresponding to position 189 of Figure 1 of the instant application). Again, an Arg is present in claims 1 and 6 of the '919 patent, the only other claims which include this amino acid sequence. Applicants have therefore added an Arg at this position in new claim 31.

Finally, claim 6 of the '919 patent appears to be missing Arg at positions 58 and 62 (corresponding to positions 144 and 148 in Figure 1 of the instant application); Lys at position 65 (corresponding to position 151 of Figure 1); and Val at position 81 (corresponding to position 167 of Figure 1). All of these amino acids are present in the other issued claims, and the specification does not discuss specific deletions at these positions. Applicants have therefore added these amino acids to new claim 35.

Support for the copied claims can be found in claims 25, 26 and 27 of the instant application, as well as throughout the specification. Claims 25, 26 and 27 recite species of the copied claims. Claim 25 recites a recombinant PDGF A-chain polypeptide comprising the amino acid sequence numbered 87-193, inclusive, of Figure 1, or an analog of this sequence which is substantially homologous and functionally equivalent thereto. This claim therefore lends support to new claims 30 through 38 (corresponding to claims 1-9 of the '919 patent). Claims 30 through 38 recite proteins that include amino acids 95 to 190, 109 to 190, 95-181, 109 to 181, 87 to 181, and 87 to 190, respectively, of Figure 1 of the instant application. Claim 36 recites unglycosylated PDGF A-chain protein. Claims 37 and 38 (corresponding to claims 8 and 9 of the '919 patent) recite that X6 is Gln and X1 is Ser, respectively. Although these positions are occupied by Asn and Cys, respectively, in Figure 1, claim 25 includes the language "substantially homologous" and therefore encompasses these substitutions. The term "substantially homologous" is defined in the specification at page 6, lines 24-27, and is meant to encompass amino acid variations (including substitutions and/or deletions).

New claims 30-38 are also supported by claims 26 and 27. Specifically, claim 26 recites PDGF A-chain polypeptides comprising (a) the amino acid sequence numbered 87 to 196 of Figure 1, or (b) the amino acid sequence numbered 87 to 196 of Figure 2, or (c) an analog of either (a) or (b) that is substantially homologous or functionally equivalent thereto. The claimed sequences of Figure 1 and 2 differ at amino acid positions 194 to 196. This claim thus supports copied claims 30-38.

Similarly, claim 27 recites a recombinant PDGF A-chain polypeptide comprising the amino acid sequence numbered 87 to 211, inclusive, of Figure 1, or an analog substantially


homologous and functionally equivalent thereto, and again reads on the subject matter of claims 30-38.

Support for claims 29-30 can be found at pages 13-14 of the instant specification.

New claim 41 is directed to a PDGF A-chain homodimer substantially free of PDGF A- and B-chain heterodimer and substantially free of PDGF B-chain homodimer. Support for this claim is inherent in the specification which is directed to PDGF A-chain. Specific support can be found at page 3, lines 8-9 and 21-22, and at page 6, lines 19-24.

Applicants respectfully request entry of the above amendments.

Respectfully submitted,
IRELL & MANELLA

By: 
Roberta L. Robins
Registration No. 33,208

545 Middlefield Road, Suite 200
Menlo Park, California 94025
Telephone: (415) 327-7250
Fax: (415) 327-2951
December 26, 1990